Clinical Trial Update: Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports termination of a Phase 1/2 study evaluating intravesical botulinum toxin in TC-3 Gel for overactive bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• TC-3 Gel (TC-3 Gel)

Snippet

Sponsor: UroGen Pharma Ltd. | Conditions: Overactive Bladder | Phase 1, Phase 2 | Status: TERMINATED